Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Selecta/JDRF Collaboration Seeks Vaccine To Prevent Or Treat Type 1 Diabetes

This article was originally published in The Pink Sheet Daily

Executive Summary

JDRF will provide milestone-based financial support toward preclinical proof of concept for a tolerogenic vaccine candidate.

You may also be interested in...



Deals of the Week: Sanofi/Selecta, Evotec/Probiodrug, Nestle/Chi-Med…

European economists meeting in London discuss drug innovation’s costs to the larger health system, research funding sources, and “sin taxes.”

Sanofi And Selecta To Partner On Immunotherapies For Life-Threatening Allergies

Vaccine and immunotherapy-focused Selecta, up to now focused on grants for funding, signs its first big pharma partner around targeted, antigen-specific programs for undisclosed allergies.

Deals Of The Week: Upsher-Smith/Proximagen, Novo Nordisk/JDRF, Newron/NeuroNova

With BIO 2012 taking place June 17-21, the entire health care world awaits the Supreme Court’s ruling on health care reform. In the pharma world, companies are strategizing against all the possible outcomes.

Related Content

Topics

UsernamePublicRestriction

Register

PS017586

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel